Alzheimers Disease Patient Registry

摘要 马约临床衰老研究（MCSA）一直是一项基于人群的认知研究 自2004年以来，在这段时间内，我们评估了 认知正常的个体患有轻度认知障碍（MCI）和痴呆。我们有 评估MCI的流行病学特征，近年来评估了MCI的许多生物标志物。 包括MRI、FDG PET、淀粉样蛋白PET和tau PET。在 目前的应用，我们将评估最近出版的国家研究所对老年痴呆症 使用我们基于人群的队列的关联AD研究框架。在目标1中，我们将预测和 使用框架的综合征临床评估认知能力下降的风险因素的作用 认知未受损、MCI和痴呆参与者的分类。在目标2中，我们将预测 根据新提出的数字分期方案， 在淀粉样蛋白阳性人群中进行的随机对照试验。此外，由于我们正在评估 我们亦会评估数字分级计划， 淀粉样蛋白阴性的人以及整个人群。因为人们认识到， 脑血管疾病在衰老中起着重要作用，在目标3中，我们将评估 脑血管病在衰老和认知中的作用及其与AD病理学的相互作用。我们将 并采用先进的方法开发新的MRI脑血管疾病措施。生物标志 AD的措施通常是昂贵的和/或侵入性的，因此，对于公众来说是不实用的。 因此，在目标4中，我们将确定和比较血浆的效用 淀粉样蛋白-β、p-tau 181、总tau和神经丝光（NfL）作为认知障碍的非侵入性生物标志物 降低并评估与淀粉样蛋白、tau蛋白、神经变性和 血管疾病最后，由于共享MCSA的丰富资源非常重要，在目标5中，我们 概述我们提出的数据共享机制，包括审查提案、标准化数据 共享数据的共享协议和物流。我们希望， MCSA将为老龄化和AD领域提供有价值的信息。

ABSTRACT The Mayo Clinic Study of Aging (MCSA) has been functioning as a population-based study of cognition and aging since 2004. Over that timeframe, we have evaluated longitudinal cognitive trajectories of individuals who are cognitively normal, have mild cognitive impairment (MCI) and dementia. We have evaluated epidemiologic features of MCI and in recent years have evaluated many of the biomarkers of aging and Alzheimer's disease (AD) including MRI, FDG PET, amyloid PET and tau PET. In the current application, we will evaluate the recently published National Institute on Aging-Alzheimer's Association AD Research Framework using our population-based cohort. In Aim 1, we will predict and assess the role of risk factors of cognitive decline using the Framework's syndromic clinical classification of cognitively unimpaired, MCI and dementia participants. In Aim 2, we will predict cognitive decline in the Framework according to the newly proposed numeric staging scheme for randomized controlled trials among amyloid positive persons. In addition, since we are evaluating a representative sample of the entire community, we will also evaluate the numerical staging scheme in amyloid negative persons as well as in the entire population. Since it is recognized that cerebrovascular disease plays an important role in aging, in Aim 3 we will evaluate the impact of cerebrovascular disease in aging and cognition as well as its interactions with AD pathology. We will also develop novel MRI cerebrovascular disease measures using advanced methods. Biomarker measures of AD are often expensive and/or invasive, and, as such, are not practical from a public health perspective, and, therefore, in Aim 4, we will determine and compare the utility of plasma amyloid-beta, p-tau181, total tau and neurofilament light (NfL) as noninvasive biomarkers of cognitive decline and assess interactions with imaging biomarkers of amyloid, tau, neurodegeneration and vascular disease. Finally, since sharing the rich resources of the MCSA are important, in Aim 5, we outline our proposed mechanisms for data sharing that include review of proposals, standardized data sharing agreements and logistics for sharing the data. We are hopeful that the continuation of the MCSA will provide valuable information for the field of aging and AD.